Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11339290,flow-rate,The flow-rate was 1 ml/min with UV detection at 229 nm.,"Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11339290/),[ml] / [min],1,57577,DB00483,Gallamine Triethiodide
,6289700,elimination halflife,"In this study of 50- to 76-year-old patients, the most striking difference from other studies was that the elimination halflife averaged 247 minutes in this study whereas 128 to 141 minutes has been reported previously.",Gallamine administered by combined bolus and infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289700/),min,247,67471,DB00483,Gallamine Triethiodide
,6289700,elimination halflife,"In this study of 50- to 76-year-old patients, the most striking difference from other studies was that the elimination halflife averaged 247 minutes in this study whereas 128 to 141 minutes has been reported previously.",Gallamine administered by combined bolus and infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6289700/),min,128 to 141,67472,DB00483,Gallamine Triethiodide
,7225266,plasma clearance,"The plasma clearance of pancuronium in patients with extrahepatic cholestasis was 16% lower than in a control group (1.47 +/- 0.11 ml min-1 kg-1 v. 1.76 +/- 0.21 ml min-1 kg-1), but the difference was not significant.",Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),[ml] / [kg·min],1.47,159130,DB00483,Gallamine Triethiodide
,7225266,plasma clearance,"The plasma clearance of pancuronium in patients with extrahepatic cholestasis was 16% lower than in a control group (1.47 +/- 0.11 ml min-1 kg-1 v. 1.76 +/- 0.21 ml min-1 kg-1), but the difference was not significant.",Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),[ml] / [kg·min],1.76,159131,DB00483,Gallamine Triethiodide
,7225266,elimination half-life T 1/2 beta,A significant increase in the elimination half-life T 1/2 beta of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment (V2) was found in patients with extrahepatic cholestasis when compared with control patients.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),min,141,159132,DB00483,Gallamine Triethiodide
,7225266,elimination half-life T 1/2 beta,A significant increase in the elimination half-life T 1/2 beta of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment (V2) was found in patients with extrahepatic cholestasis when compared with control patients.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),min,224,159133,DB00483,Gallamine Triethiodide
,7225266,cumulative biliary excretion,There was a significantly lower cumulative biliary excretion of pancuronium (0.3 +/- 0.3% v. 10.9 +/- 3.2% in the controls) during the 48-h period of observation.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,0.3,159134,DB00483,Gallamine Triethiodide
,7225266,cumulative biliary excretion,There was a significantly lower cumulative biliary excretion of pancuronium (0.3 +/- 0.3% v. 10.9 +/- 3.2% in the controls) during the 48-h period of observation.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,10.9,159135,DB00483,Gallamine Triethiodide
,7225266,cumulative urinary excretion,The cumulative urinary excretion of gallamine during 48 h in both groups of patients was approximately 100%.,Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7225266/),%,100,159136,DB00483,Gallamine Triethiodide
,7371705,distribution phase half-life (t1/2 alpha),No significant differences were noted when the model-independent pharmacokinetic parameters between the two groups of patients were compared with the exception of the distribution phase half-life (t1/2 alpha) (6.70 min single vs 9.19 min multiple p less than 0.05).,Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),min,6.70,182418,DB00483,Gallamine Triethiodide
,7371705,distribution phase half-life (t1/2 alpha),No significant differences were noted when the model-independent pharmacokinetic parameters between the two groups of patients were compared with the exception of the distribution phase half-life (t1/2 alpha) (6.70 min single vs 9.19 min multiple p less than 0.05).,Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),min,9.19,182419,DB00483,Gallamine Triethiodide
,7371705,half-life (t1/2 beta),"Mean values for the pooled data for the half-life (t1/2 beta), plasma clearance (Clp) and volume of distribution (Vd beta) were 134.58 min, 1.20 ml/min/kg and 225.28 ml/kg respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),min,134.58,182420,DB00483,Gallamine Triethiodide
,7371705,plasma clearance (Clp),"Mean values for the pooled data for the half-life (t1/2 beta), plasma clearance (Clp) and volume of distribution (Vd beta) were 134.58 min, 1.20 ml/min/kg and 225.28 ml/kg respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[ml] / [kg·min],1.20,182421,DB00483,Gallamine Triethiodide
,7371705,volume of distribution (Vd beta),"Mean values for the pooled data for the half-life (t1/2 beta), plasma clearance (Clp) and volume of distribution (Vd beta) were 134.58 min, 1.20 ml/min/kg and 225.28 ml/kg respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[ml] / [kg],225.28,182422,DB00483,Gallamine Triethiodide
,7371705,recovery rate,Linear regression of the offset data (20 to 80% paralysis) in 10 patients revealed a recovery rate of 0.35 to 1.33%/min.,Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[%] / [min],0.35 to 1.33,182423,DB00483,Gallamine Triethiodide
,7371705,effective plasma concentrations,"For 5 patients where offset data was available over the entire range of response (0 to 100%) the calculated mean effective plasma concentrations for gallamine at 50 and 95% paralysis (ECp50, ECp95) were found to vary between 3.43 to 10.28 micrograms/ml, and 5.66 to 23.37 micrograms/ml respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[μg] / [ml],3.43 to 10.28,182424,DB00483,Gallamine Triethiodide
,7371705,effective plasma concentrations,"For 5 patients where offset data was available over the entire range of response (0 to 100%) the calculated mean effective plasma concentrations for gallamine at 50 and 95% paralysis (ECp50, ECp95) were found to vary between 3.43 to 10.28 micrograms/ml, and 5.66 to 23.37 micrograms/ml respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[μg] / [ml],5.66 to 23.37,182425,DB00483,Gallamine Triethiodide
,7371705,"ECp50, ECp95)","For 5 patients where offset data was available over the entire range of response (0 to 100%) the calculated mean effective plasma concentrations for gallamine at 50 and 95% paralysis (ECp50, ECp95) were found to vary between 3.43 to 10.28 micrograms/ml, and 5.66 to 23.37 micrograms/ml respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[μg] / [ml],3.43 to 10.28,182426,DB00483,Gallamine Triethiodide
,7371705,"ECp50, ECp95)","For 5 patients where offset data was available over the entire range of response (0 to 100%) the calculated mean effective plasma concentrations for gallamine at 50 and 95% paralysis (ECp50, ECp95) were found to vary between 3.43 to 10.28 micrograms/ml, and 5.66 to 23.37 micrograms/ml respectively.",Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7371705/),[μg] / [ml],5.66 to 23.37,182427,DB00483,Gallamine Triethiodide
,11920762,-plasma partition coefficient,Gallamine was rapidly distributed into MIF with a MIF-plasma partition coefficient of 0.9 +/- 0.1 (n = 6).,Muscle distribution of the neuromuscular blocker gallamine using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11920762/),,0.9,199314,DB00483,Gallamine Triethiodide
,11395330,flow rate,In vitro recovery of gallamine from the microdialysis probe when different perfusion flow rates were employed was evaluated leading to selection of a flow rate of 2 microl/min with 15-min sampling intervals for the subsequent studies.,Assessment of in vitro and in vivo recovery of gallamine using microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11395330/),[μl] / [min],2,233959,DB00483,Gallamine Triethiodide
